Diagnostic Value of Urinary Steroid Profiling in the Evaluation of Adrenal Tumors by T. M. A. Kerkhofs et al.
ORIGINAL PAPER
Diagnostic Value of Urinary Steroid Profiling in the Evaluation
of Adrenal Tumors
T. M. A. Kerkhofs1 & M. N. Kerstens2 & I. P. Kema3 & T. P. Willems4 & H. R. Haak1,5,6
Received: 21 January 2015 /Accepted: 5 May 2015 /Published online: 19 May 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Radiological examination may unexpectedly reveal
an adrenal mass. Current algorithms for differentiating be-
tween benign and malignant lesions mainly rely on size and
densitometry on unenhanced CT, which have limited specific-
ity. We examined the diagnostic value of urinary steroid pro-
filing by gas chromatography/mass-spectrometry (GC/MS) in
differentiating between benign and malignant adrenal tumors.
A retrospective study in two referral centers for patients with
adrenal disease was performed. All urinary steroid profiles
ordered for evaluation of an adrenal tumor between January
2000 and November 2011 were examined. Patients were di-
agnosed with adrenal cortical carcinoma (ACC), adrenal cor-
tical adenoma (ACA), or other adrenal mass. Results of hor-
monal measurements, imaging studies, pathology reports, and
clinical outcome were retrieved from medical records. The
diagnostic value of individual urinary steroid metabolites
was determined by receiver operating characteristics analysis.
Cut-off values were compared to reference values from an age
and gender-standardized population of healthy controls. Eigh-
teen steroid metabolites were excreted in significantly higher
concentrations in patients with ACC (n=27) compared to pa-
tients with ACA (n=107) or other adrenal conditions (n=18).
Tetrahydro-11-deoxycortisol (THS) at a cut-off value of
2.35 μmol/24 h differentiated ACC from other adrenal disor-
ders with 100 % sensitivity and 99 % specificity. Elevated
urinary excretion of THS was associated with a very high
sensitivity and specificity to differentiate between an ACC
and a benign adrenal mass. Urinary steroid profiling might
be a useful diagnostic test for the evaluation of patients with
an adrenal incidentaloma.
Introduction
An adrenal incidentaloma is an adrenal mass found coinciden-
tally during a radiologic examination performed for reasons
other than evaluation for adrenal disease [1]. The estimated
prevalence of adrenal incidentalomas ranges from about 0.1 %
for general health screening with ultrasonography to 4.4 % in
older subjects examinedwith high-resolution CTscanning [2].
Optimal clinical management of adrenal incidentalomas has
not been established as none of the proposed diagnostic algo-
rithms has been validated prospectively [1, 3–5]. Key objec-
tives of these algorithms are to determine whether hormonal
overproduction and/or malignant disease is present. The re-
ported frequency of adrenocortical carcinoma (ACC) among
patients with adrenal incidentaloma varies from 1.2–12 % [5].
Assessment of malignancy risk is predominantly based on
radiological characteristics such as size, shape, and attenua-
tion value of the adrenal mass. In addition, follow-up by mon-
itoring growth rate with repeat CT or MRI-scans at various
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intervals during 1 to 2 years after discovery is generally ad-
vised for those patients not undergoing surgery after the initial
evaluation [1, 4–7]. However, a strategy of repeat imaging is
associated with certain risks for the patient and is unlikely to
be cost-effective [8]. Urinary steroid profiling (USP) might
offer an alternative diagnostic tool for discriminating between
ACC and non-ACC in individuals presenting with an adrenal
incidentaloma, as it has been shown that ACC is often accom-
panied by alterations in the urinary steroid metabolome
[9–11]. Currently, only few studies have examined the poten-
tial diagnostic value of USP in individuals harboring an adre-
nal tumor [12–15]. Except for the study by Arlt et al. [13],
these studies described a small number of subjects. Therefore,
the primary objective of our study was to determine the diag-
nostic performance of USP in differentiating ACC from non-
ACC in a large cohort of patients with adrenal tumors.
Patients and Methods
Both Máxima Medical Center (MMC) and University Medi-
cal Center Groningen (UMCG) are referral centers for patients
with adrenal disease. We retrospectively analyzed all urinary
steroid profiles ordered for evaluation of an adrenal tumor at
UMCG and MMC from January 1, 2000 until November 1,
2011. In addition, we included all adult patients with ACC
diagnosed from January 1, 2011 until January 1, 2014 in
whom a baseline urinary steroid profile was performed. The
correspondingmedical records were examined and the follow-
ing data were retrieved: age, gender, symptoms, and signs,
laboratory measurements (i.e., hormonal tests), imaging stud-
ies, treatment, pathology reports, clinical outcome, and fol-
low-up.
Endocrine activity of the tumor was determined based on
the results of locally applied hormonal assays. Glucocorticoid
excess was defined as an abnormal result of the 1 mg over-
night dexamethasone suppression test (cut-off value serum
cortisol at 50 nmol/L) and/or as an elevated 24 h urinary free
cortisol excretion. Serum aldosterone to plasma renin ratio
was determined to screen for primary aldosteronism, serum
dehydro-epiandrosteronesulfate (DHEAS), and testosterone
were measured to demonstrate hyperandrogenism (cut-off
values based on individual age and gender-related upper ref-
erence limits). Plasma-free metanephrines or urinary fraction-
ated metanephrines were measured to detect a pheochromo-
cytoma. Tumor size and unenhanced CT attenuation values
were collected from the original radiological examination re-
port. In case these were not reported, the original CT studies
were re-examined by an experienced radiologist.
The final diagnosis was based on either the pathological
examination of the resected adrenal gland or on the clinical
course including the results of follow-up imaging studies in
patients who did not undergo surgery. In patients with ACC,
the Weiss score (a set of nine histopathological criteria with
prognostic value in adrenocortical tumors) was extracted from
the original pathology reports and disease progression was
staged according to the European Network for Study of Ad-
renal Tumors (ENSAT) staging system [16, 17]. Patients in
whom a final diagnosis of pheochromocytomawasmadewere
excluded from the present study.
Gas chromatography/mass-spectrometry (GC/MS) for de-
termination of the USP was performed at the department of
laboratory medicine of the UMCG. In summary, free and con-
jugated steroids were extracted from 1-mL urine by liquid-
liquid extraction. Enzymatic hydrolyzation, re-extraction,
and chemical derivatization formed methyloxime-trimethyl-
silyl ethers from steroid conjugates. An Agilent 5973 instru-
ment operating in selected ion-monitoring (SIM) mode was
used to achieve sensitive and specific detection and quantifi-
cation of 22 selected steroid metabolites [18].
Reference values for USP were established in a group of
healthy volunteers (n=240) recruited from the LifeLines co-
hort, a three-generation population-based study [19]. These
subjects were stratified according to gender and age, with
age ranging from 20 to 79 years and each decade comprising
40 subjects (male-to-female ratio 1:1).
Statistical Analysis
Demographical characteristics were assessed using ANOVA
for continuous variables and Pearson’s chi-squared test for
categorical variables. Between-group differences in steroid
excretion were evaluated using the Kruskal-Wallis test follow-
ed by post hoc analysis using the Mann-Whitney test with
Bonferroni adjustment (α=0.008). Receiver operating charac-
teristics (ROC) curves were generated for those individual
urinary metabolites which displayed a significant between-
group difference. Sensitivity and specificity were calculated
at cut-off values providing highest sensitivity. Cut-off values
were compared with age- and gender-dependent reference
values. Correlation between histological characteristics and
steroid excretion in patients with ACC was calculated using
Pearson’s correlation analysis and expressed as Pearson’s r. A
two-sided P value <0.05 was considered to be significant.
Data management and statistical analyses were performed
using Prism 6.0 (GraphPad Software, La Jolla, USA) and
SPSS 19.0 (IBM, Armonk, USA).
Results
Patients
We evaluated 152 patients with an adrenal tumor (52
males, 100 females), and demographical characteristics
are summarized in Table 1. The following diagnoses
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were established: adrenocortical carcinoma (ACC; n=
27) and adrenocortical adenoma (ACA; n=107). In ad-
dition, there was a mixed group of 18 patients with a
variety of diagnoses: benign myelolipoma (n=4), metas-
tasis from an extra-adrenal primary tumor (n=4), adre-
nal hyperplasia (n=2), multinodular hyperplasia (n=2),
cavernous lymphangioma (n=1), ganglioneuroma (n=1),
hemangioma (n=1), cyst (n=1), non-Hodgkin lymphoma
(n=1) and leiomyosarcoma (n=1). The majority of these
pat ients were analyzed because of an adrenal
incidentaloma (n=109, 72 %).
A diagnosis of ACC was histologically confirmed in 25
subjects (93 %). Median Weiss-score was 6 (range 4-8). In
the remaining 2 patients, a clinical diagnosis of ACC was
made based on imaging studies showing an adrenal tumor
with metastases in combination with biochemical evidence
of steroid hypersecretion. At presentation, the tumor stages
according to the ENSAT classification were II (n=10), III
(n=6) and IV (n=11) [16]. Hormonal overproduction was
present in 20 patients (74 %); hypercortisolism (n=18),
hyperandrogenism (n=14), and hyperestrogenism (n=1). His-
tological confirmation was obtained in 28 subjects with ACA
(26 %) and in 13 patients from the mixed group (68 %). In the
remainder of subjects, a diagnosis of ACAwas established by
biochemical and imaging studies as well as by clinical follow-
up (median 52 months; range 3–167 months). Patients with
functioning ACA demonstrated hypercortisolism (n=19) or
primary aldosteronism (n=3).
Radiological Characteristics
Patients underwent radiological imaging with CT (n=126)
and/or MRI (n=29). Median tumor size in patients with
ACC was 10.0 cm (range 5.3–17.0 cm), significantly larger
than the lesion size in patients with ACA (2.9 cm; range 0.8–
10.0 cm) or in patients from the mixed group (7.4 cm; range
2.3–14.0 cm, P<0.001 for both; Table 1).
An unenhanced abdominal CT scan was performed in 78
patients (51 %). All adrenal lesions with attenuation value ≤10
HU (n=37) were found to be benign. The 41 adrenal tumors
with an unenhanced attenuation value >10 HU included ACC
(n=13), ACA (n=24), metastatic lesions (n=2), benign
myelolipoma (n=1), and a leiomyosarcoma (n=1). At a cut-
off value of 10 HU, unenhanced CT densitometry was 100 %
sensitive and 57 % specific for the presence of ACC.
Steroid Metabolite Excretion
Eighteen steroid metabolites were excreted in significantly larg-
er quantities by patients with ACC compared to patients with
non-ACC-related adrenal masses (Fig. 1). In contrast, patients
with ACC excreted less of the metabol i te a l lo-
tetrahydrocorticosterone (allo-THB) compared to subjects with-
out ACC (P=0.019). There were no significant differences in
individual metabolite excretion between the groups with func-
tioning ACA, non-functioning ACA, and the mixed group.












Age (years) [mean±SD] 56±13 57±14 50±12 58±12 54±17 0.043*
Sex [n (%)] Male 52 (34) 8 (30) 6 (27) 28 (33) 10 (56) 0.219
Female 100 (66) 19 (70) 16 (73) 57 (67) 8 (44)
BMI (kg/m2)
[mean±SD]




Glucocorticoids 38 (25) 18 (67) 19 (86) 0 1 (6) –
Androgens 14 (9) 14 (52) 0 0 0
Estrogens 1 (1) 1 (4) 0 0 0
















≤10 37 0 6 28 3 –
>10 41 13 2 22 4
n/a 74 14 14 35 11
P value for comparison between groups, n/a: unenhanced CT scan was not performed
ACC adrenocortical carcinoma, ACA adrenocortical adenoma, BMI body mass index
*Mann-WhitneyU test with Bonferroni correction for comparison between individual groups (α=0.008) between ACAfunctioning and ACAnon-functioning,
P=0.005; other comparisons did not show significant results
**Mann-Whitney U test with Bonferroni correction for comparison between individual groups (α=0.008) between ACC and ACAfunctioning, P<0.001;
between ACC and ACAnon-functioning, P<0.001; between ACC and other, P=0.003; between ACAnon-functioning and other, P<0.001; and between
ACAfunctioning and other, P=0.001
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ROC-analysis demonstrated that 15 steroid metabolites
had a sensitivity >90 % for detecting ACC, of which 7 had
a sensitivity of 100 % (i.e., tetrahydro-11-deoxycortisol
(THS), pregnanediol (P2), pregnanetriol (P3), etiocholanol-
one (E) , and ros te rone , t e t r ahydrocor t i so l , and
tetrahydrocortisone; Table 2). The ROC curve for THS was
found to have the largest AUC (1.0), with a sensitivity of
100 % and a specificity of 99 % at a cut-off value of
2.35 μmol/24 h (Fig. 2). This cut-off value significantly
exceeded each of the age and gender-specific upper reference
limits. Median THS excretion in patients with ACC, ACA, or
those belonging to the mixed group was 13.10 μmol/24 h
(interquartile range 6.20–35.90 μmol/24 h), 0.30 μmol/24 h
(IQR 0.20–0.65 μmol/24 h), and 0.40 μmol/24 h (IQR 0.20–
0.63 μmol/24 h), respectively. Excluding patients in whom
the adrenal tumor had a CTattenuation value <10 HU (n=37)
did not affect the diagnostic performance of THS excretion
(AUC 1.0). Figure 3 displays the relationship between cut-off
values, reference intervals, and median excretion of four ste-
roid metabolites showing the highest sensitivity and specific-
ity (THS, P2, P3, E).
Median THS excretion in patients with ACC and ENSAT
stages II, III, or IV was 8.70 μmol/24 h (range 2.40–
45.20 μmol/24 h), 10.00 μmol/24 h (range 3.30–
39.20 μmol/24 h), and 30.40 μmol/24 h (range 6.20–
250.00 μmol/24 h), respectively (P=0.025). Histopathologi-
cal description of diameter and weight of the ACC was avail-
able for 23 and 13 patients, respectively. We found a
Fig. 1 a–d. Median urinary excretion of 22 metabolites in patients with
ACC, functioning adenoma, non-functioning adenoma, or other adrenal
tumors organized per steroid class. A androsterone, E etiocholanolone,
DHEA dehydroepiandrosterone, 11-KE 11-keto-etiocholanolone, 11-HA
11-hydroxy-androsterone, 11-HE 11-hydroxy-eticholanolone, THE
tetrahydrocortisone, THF tetrahydrocortisol, allo-THF allo-
tetrahydrocortisol, THA tetrahydro-11-dehydrocorticosterone, THB
tetrahydrocorticosterone, allo-THB allo-tetrahydrocorticosterone, allo-
P2 allo-pregnanediol, P2 pregnanediol, P3 pregnanetriol, Polone epi-
pregnanolone, THS tetrahydro-11-deoxycortisol, PDL pregnanediolone,
PTL pregnanetriolone. Whiskers indicate range, * indicates significant
difference between ACC and other groups
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significant correlation between THS excretion and ACC di-
ameter (r=0.477, P=0.021) and a near-significant correlation
between THS excretion and ACC weight (r=0.553,
P=0.050).
Table 2 Receiver operating
characteristics for individual
steroid metabolites with
sensitivity for detecting ACC
>90 %
Metabolite AUC Cut-off value (μmol/24 h) Sensitivity (%) Specificity (%)
THS 1.000 2.35 100 99
P2 0.975 0.66 100 60
P3 0.960 1.45 100 61
E 0.960 2.47 100 53
A 0.839 0.35 100 14
THF 0.806 2.10 100 5
THE 0.700 3.20 100 4
PDL 0.884 0.15 96 26
11-KE 0.733 0.49 96 18
β-cortolone 0.793 0.45 96 7
α-cortolone 0.760 0.75 96 5
α-cortol 0.789 0.15 96 4
11-HA 0.699 0.15 96 2
11-HE 0.761 0.49 93 25
Polone 0.922 0.15 91 83
AUC area under curve, THS tetrahydro-11-deoxycortisol, P2 pregnanediol, P3 pregnanetriol, E etiocholanolone,
A androsterone, THF tetrahydrocortisol, THE tetrahydrocortisone, PDL pregnanediolon, 11-KE 11-keto-etiochol-
anolone, 11-HA 11-hydroxy-androsterone, 11-HE 11-hydroxy-eticholanolone, Polone epi-pregnanolone
Fig. 2 a–d. Receiver operating
characteristic (ROC) curve for
tetrahydro-11-deoxycortisol,
pregnanediol, pregnanetriol, and
etiocholanolone for the diagnosis
of adrenocortical carcinoma
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Discussion
In a relatively large cohort of patients with primary adrenal
tumors, we found that urinary steroid profiling (USP) by gas
chromatography/mass-spectrometry discriminates ACC from
non-ACC with high diagnostic accuracy. In particular, we
demonstrated that measurement of THS had the highest diag-
nostic test performance with a sensitivity and specificity of
100 and 99 %, respectively. In addition, THS excretion was
significantly correlated with ACC tumor size and stage.
It has been demonstrated in several studies that USP may
often reveal an increased excretion of steroid metabolites in
patients with ACC, even in those without clinical signs of
hormonal overproduction [10, 12, 14, 15, 20]. These observa-
tions suggest that USP might be a useful diagnostic tool in
order to determine whether an adrenal tumor is either malig-
nant or benign. Nearly all studies included a small number of
patients with an adrenal tumor, limiting the external validity of
these data. So far, only the study by Arlt et al. had a size
comparable to the current series [13]. These investigators
established a specificity and sensitivity of both 88 % for the
nine most differentiating steroid metabolites after conducting
a more complex analysis, i.e., generalized matrix learning
vector quantization. In addition, they also identified THS as
the most discriminative steroid in differentiating benign from
malignant adrenal tumors. There are some differences be-
tween the present study and the one by Arlt et al. which might
explain why we established a higher diagnostic performance
for USP. In all our subjects, USP was performed before re-
moval of the primary ACC. In contrast, 22 % of patients with
ACC in the study byArlt et al. were examined after removal of
the primary tumor because of the presence of metastases. In
view of the here described correlation between tumor size and
THS excretion, it seems likely that the difference in diagnostic
performance of USP can be partially explained by variation in
tumor burden between the two populations at study. Presum-
ably, a gradual increase in urinary THS occurs during devel-
opment of metastatic disease. During follow-up after primary
resection, THS levels below this cut-off value may not ex-
clude the presence of residual or recurrent disease.
The etiology of THS overproduction in ACC remains spec-
ulative. Under physiological conditions, ACTH stimulates the
conversion of free cholesterol to pregnenolone in mitochon-
dria. Further steroid hormone biosynthesis takes place on the
endoplasmic reticulum, except for the final steps in glucocor-
ticoid and mineralocorticoid synthesis [21]. These reactions,
catalyzed by CYP11B1 (11-deoxycortisol→cortisol) and
CYP11B2 (11-deoxycorticosterone→aldosterone), take place
on the inner mitochondrial membrane (IMM) and are stimu-
lated by ACTH [22]. The abundant presence of THS, a me-
tabolite of 11-deoxycortisol, suggests a relative deficiency of
otherwise normally functioning CYP11B1 and/or dysfunction
of the enzyme itself [13, 23]. Possible explanations for a rel-
ative deficiency include increased production of steroid pre-
cursors upstream due to malignant proliferation or impaired
access of substrate to the IMM. Dysfunction of CYP11B1
Fig. 3 a–d. Relationship between cut-off values, reference values, and measured urinary excretion of tetrahydro-11-deoxycortisol, pregnanediol,
pregnanetriol, and etiocholanolone in 27 ACC patients
HORM CANC (2015) 6:168–175 173
may be caused by mutational changes inherent to ACC or
diminished ACTH secretion due to negative feedback by in-
creased levels of steroid precursors.
The results of our study suggest that USP could be a valu-
able diagnostic tool in analyzing an adrenal incidentaloma.
Current diagnostic algorithms mainly depend on radiological
characteristics for differentiation between benign and malig-
nant adrenal tumors [1, 4–7]. CT scanning, however, has sev-
eral disadvantages such as exposure to ionizing radiation, ad-
verse effects of radiocontrast (nephropathy, allergic reactions),
and costs [8]. Thus, USP might offer a patient friendly, entire-
ly safe, and less expensive alternative diagnostic test for the
evaluation of an adrenal incidentaloma. Further validation of
this test is warranted and is the main objective of a recently
started multicenter prospective study in the Netherlands
(NCT02324647).
Like previous studies on this subject, the value of our study
is limited by its retrospective design. In addition, selection
bias could have influenced the results since it cannot be guar-
anteed that all patients with an adrenal tumor were evaluated
with USP. Moreover, not all diagnoses were confirmed by
histopathological examination. This is, however, in agreement
with the clinical practice to exclude the diagnosis of ACC in
case symptoms or signs suggestive for adrenal malignancy
have not occurred during long-term follow-up of the patient.
In conclusion, USP might be a useful diagnostic tool for
discriminating between benign and malignant adrenocortical
tumors. In particular, increased urinary excretion of THS was
associated with an almost perfect diagnostic power. Prospec-
tive studies are required to establish the true diagnostic value
of USP in patients with an adrenal incidentaloma.
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